Coincidental SARS-CoV-2 infection and mRNA vaccination: a case report addressing the most important clinical questions.
Antibodies
COVID-19
Coincidental
Infection
Vaccination
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
03
03
2021
accepted:
16
04
2021
pubmed:
9
5
2021
medline:
19
8
2021
entrez:
8
5
2021
Statut:
ppublish
Résumé
The case describes the coincidental mRNA vaccination and SARS-CoV-2 infection of a 31-year-old physician addressing the theoretical considerations and recommendations for further actions in such a particular constellation that we will expect more often in the near future.
Identifiants
pubmed: 33963523
doi: 10.1007/s15010-021-01613-w
pii: 10.1007/s15010-021-01613-w
pmc: PMC8104037
doi:
Substances chimiques
COVID-19 Vaccines
0
Vaccines, Synthetic
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
785-788Informations de copyright
© 2021. The Author(s).
Références
Tedros Adhanom Ghebreyesus. WHO Director—General’s opening remarks at the media briefing on COVID-19—11 March 2020 [Internet]. 2020. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 . cited 9 Jan 2021.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383:2603–15.
doi: 10.1056/NEJMoa2034577
Long Q-X, Liu B-Z, Deng H-J, Wu G-C, Deng K, Chen Y-K, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26:845–8.
doi: 10.1038/s41591-020-0897-1
Qu J, Wu C, Li X, Zhang G, Jiang Z, Li X, et al. Profile of immunoglobulin g and igm antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71:2255–8.
doi: 10.1093/cid/ciaa489
Lu L, Zhang H, Zhan M, Jiang J, Yin H, Dauphars DJ, et al. Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development? Sci China Life Sci. 2020;63:1833–49.
doi: 10.1007/s11427-020-1859-y
Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al. COVID-19 vaccine BNT162b1 elicits human antibody and T H 1 T cell responses. Nature. 2020;586:594–9.
doi: 10.1038/s41586-020-2814-7
Walsh EE, Robert W. Frenck J, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and Immunogenicity of two RNA-based COVID-19 vaccine candidates. N Engl J Med. Massachusetts Medical Society; 2020. https://www.nejm.org/doi/ https://doi.org/10.1056/NEJMoa2027906 . Cited 10 Jan 2021.
Martin LK, Hollaus A, Stahuber A, Hübener C, Fraccaroli A, Tischer J, et al. Cross-sectional analysis of CD8 T cell immunity to human herpesvirus 6B. PLOS Pathog. 2018;14:e1006991.
doi: 10.1371/journal.ppat.1006991
Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586:589–93.
doi: 10.1038/s41586-020-2639-4
Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines | CDC [Internet]. 2021. https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html . Cited 23 Feb 2021.